Vaccine policy in the United States is undergoing one of its most turbulent periods in decades. Longstanding systems that once guided doctors, hospitals, schools, and insurers are now under intense scrutiny following dramatic changes at the U.S. Centers for Disease Control and Prevention. In response to growing concern among public health experts, the American Medical Association and the University of Minnesota Vaccine Integrity Project have announced the creation of an independent vaccine review initiative.
This move follows widespread criticism of recent federal decisions affecting vaccine recommendations, particularly after the removal of the entire Advisory Committee on Immunization Practices. The new effort aims to restore confidence by providing science based evaluations of vaccine safety and effectiveness, without issuing formal recommendations.
As the nation prepares for the next respiratory virus season, the debate over who should guide vaccine policy has taken center stage.
For decades, vaccine guidance in the United States relied heavily on the Advisory Committee on Immunization Practices, commonly known as ACIP. This CDC panel reviewed extensive scientific data before recommending which vaccines should be administered and to whom.
Although ACIP recommendations were not legally binding, they shaped medical practice nationwide. Pediatric vaccination schedules, school requirements, and insurance coverage decisions often followed ACIP guidance closely.
That structure changed abruptly earlier this year when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. removed all 17 members of ACIP. The panel was reconstituted with new members, several of whom have expressed skepticism about vaccines.
In addition, federal officials limited participation from several major medical organizations during vaccine analyses. These changes prompted alarm across the medical and public health communities.
On Feb. 11, 2026, the American Medical Association and the Vaccine Integrity Project at the University of Minnesota announced a joint initiative to independently review vaccine evidence.
According to a joint statement, the organizations believe the CDC vaccine review process has effectively collapsed, creating an urgent need for an alternative source of trusted scientific evaluation.
The new review system will initially focus on vaccines for influenza, COVID 19, and respiratory syncytial virus. These vaccines are especially relevant ahead of the fall respiratory virus season, when hospitalizations and deaths typically rise.
The initiative does not aim to replace federal authority or issue official vaccine recommendations. Instead, it seeks to provide transparent, evidence based reviews that physicians, state health officials, and policymakers can rely on when making decisions.
The American Medical Association has historically focused on physician reimbursement, billing practices, and regulatory issues rather than large scale public health evidence reviews. Its decision to participate in this initiative signals how serious many in the medical community believe the current situation has become.
Dr. Sandra Adamson Fryhofer, an AMA trustee and liaison to the CDC vaccine panel, emphasized the organization’s responsibility to ensure the public has access to credible guidance.
She stated that health care professionals have a duty to work across medicine, science, and public health to maintain a transparent and evidence based process for vaccine decisions.
The AMA’s participation lends significant institutional weight to the initiative and underscores concerns about the current federal approach.
The Vaccine Integrity Project is based at the University of Minnesota and is led by experts in infectious disease research and public health policy. The group has already conducted independent evidence reviews of COVID 19, flu, and RSV vaccines during 2025.
It is currently reviewing data related to the human papillomavirus vaccine.
Michael Osterholm, director of the University of Minnesota Center for Infectious Disease Research and Policy, described the initiative as an effort to fill a major void in public health and medical practice.
According to Osterholm, the absence of a widely trusted federal review process has created uncertainty for clinicians and policymakers alike.
Public unease intensified after the restructured ACIP panel voted to end the longstanding recommendation that all newborns receive the hepatitis B vaccine. This decision marked a significant departure from decades of established medical guidance.
Experts also raised concerns when routine childhood vaccine recommendations were scaled back earlier in the year. These changes bypassed both CDC experts and the advisory panel entirely.
Dr. Jeanne Marrazzo, CEO of the Infectious Diseases Society of America, described the situation as deeply troubling. She noted that the developments raise serious questions about the future of evidence based vaccine recommendations in the United States.
Marrazzo emphasized that the new independent review effort represents an important step into a space that has traditionally been anchored by federal leadership.
The Department of Health and Human Services has pushed back strongly against claims that the CDC vaccine review process has collapsed.
Andrew Nixon, a spokesperson for HHS, stated that ACIP continues to function as the nation’s advisory body for vaccine recommendations driven by gold standard science.
He argued that outside organizations conducting their own analyses risk confusing the public and do not replace or supersede the federal process that guides vaccine policy.
Despite these assurances, skepticism remains high among medical professionals, particularly as recent decisions diverge from long accepted standards of care.
The emergence of an independent vaccine review system highlights a growing divide in how scientific evidence is interpreted and applied at the national level.
For physicians, inconsistent or controversial guidance can complicate conversations with patients. Vaccine confidence relies heavily on trust, not only in the products themselves but also in the institutions that evaluate them.
Patients may encounter conflicting messages from federal agencies, medical associations, and independent researchers. This fragmentation risks undermining public confidence at a time when vaccine preventable diseases remain a serious threat.
The AMA and Vaccine Integrity Project hope their reviews will provide clarity rather than confusion by focusing strictly on transparent analysis of existing data.
Vaccines undergo rigorous testing for safety and effectiveness before approval. However, post approval surveillance and ongoing evidence reviews are essential to account for real world data, emerging variants, and long term outcomes.
Independent review systems are not inherently problematic. In many scientific fields, multiple groups evaluating the same data can strengthen conclusions.
The concern arises when trusted federal processes are perceived as politicized or weakened. In such cases, independent efforts may be seen as necessary safeguards rather than sources of confusion.
Maintaining public trust requires consistency, transparency, and a clear separation between scientific evidence and political influence.
With influenza, COVID 19, and RSV posing ongoing risks, the timing of this initiative is significant. Health systems will soon need to finalize vaccination strategies for the upcoming season.
Doctors and public health officials may increasingly turn to independent reviews when assessing vaccine benefits and risks.
Whether this effort ultimately restores confidence or further highlights divisions remains to be seen. What is clear is that vaccine policy in the United States is entering a new and uncertain phase.
The decision by the American Medical Association and the University of Minnesota Vaccine Integrity Project to launch an independent vaccine review reflects profound concern within the medical community.
Amid sweeping changes at the CDC and controversial federal decisions, many experts fear that evidence based vaccine guidance is being undermined.
While federal officials insist the existing system remains intact, the creation of an alternative review process underscores a growing trust gap.
As respiratory virus season approaches, the stakes are high. Clear, science driven information will be essential for protecting public health and maintaining confidence in vaccines that have saved countless lives.
The Washington Post, Feb. 10, 2026
This article is for informational purposes only and does not provide medical advice. Statistical data and public health information describe general trends and may not apply to individual circumstances. Always consult a qualified healthcare professional for personalized medical guidance and vaccination decisions.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.